MOLECULAR MECHANISMS REGULATING CD19, CD20 AND CD22 GENE-EXPRESSION

被引：71

作者：

KEHRL, JH

RIVA, A

WILSON, GL

THEVENIN, C

机构：

[1] John H. Kehrl, Agostino Riva, Gaye Lynn Wilson and Claire Thévenin are in the Section of B Cell Molecular Immunology, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda

来源：

IMMUNOLOGY TODAY | 1994年 / 15卷 / 09期

关键词：

D O I：

10.1016/0167-5699(94)90273-9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The CD19, CD20 and CD22 genes encode transmembrane proteins that are of vital importance to B-cell function. Similar to the immunoglobulin (Ig) genes, they are expressed in a lineage-specific and developmentally regulated manner. Here, John Kehrl and colleagues describe how an understanding of the transcriptional regulation of the CD19, CD20 and CD22 genes is leading to valuable insights into some of the important molecular events that occur in B-cell development and differentiation.

引用

页码：432 / 436

页数：5

共 50 条

[21] Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
Qin, Haiying
Haso, Waleed
Sang Minh Nguyen
Fry, Terry J.
BLOOD, 2015, 126 (23)
[22] Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Qin, Haiying
Ramakrishna, Sneha
Nguyen, Sang
Fountaine, Thomas J.
Ponduri, Anusha
Stetler-Stevenson, Maryalice
Yuan, Constance M.
Haso, Waleed
Shern, Jack F.
Shah, Nirali N.
Fry, Terry J.
MOLECULAR THERAPY-ONCOLYTICS, 2018, 11 : 127 - 137
[23] CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling
Sato, S
Jansen, PJ
Tedder, TF
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) : 13158 - 13162
[24] Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Francoise
Spertini, Olivier
BIOMARKER RESEARCH, 2021, 9 (01)
[25] Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Sophie Voruz
Sabine Blum
Laurence de Leval
Jacqueline Schoumans
Françoise Solly
Olivier Spertini
Biomarker Research, 9
[26] POSSIBLE ROLE OF CD22, CD79B AND CD20 EXPRESSION IN DISTINGUISHING SMALL LYMPHOCYTIC LYMPHOMA FROM CHRONIC LYMPHOCYTIC LEUKEMIA
Jovanovic, Danijela
Djurdjevic, Predrag
Andjelkovic, Nebojsa
Zivic, Ljubica
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (06) : 405 - 405
[27] Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia
Jovanovic, Danijela
Djurdjevic, Predrag
Andjelkovic, Nebojsa
Zivic, Ljubica
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (01): : 29 - 33
[28] PREVALENCE AND CLINICAL CHARACTERIZATION OF CD20 AND CD22 EXPRESSION IN PEDIATRIC PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Rayburg, Melissa S.
Marmer, Daniel
Mo, Jun
McMasters, Richard
Smolarek, Teresa
Lampkin, Beatrice
Perentesis, John
PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 718 - 718
[29] Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+ CD22+, CD19-, and CD22- Pre-B Leukemia
Qin, Haiying
Nguyen, Sang M.
Ramakrishna, Sneha
Tarun, Samiksha
Yang, Lila
Verdini, Nicholas Peter
Haso, Waleed
Fry, Terry J.
BLOOD, 2017, 130
[30] A PANEL OF CD19 DEFICIENT B-CELL LINES PROVIDES INSIGHTS INTO THE MECHANISMS REGULATING CD19 GENE-TRANSCRIPTION
RIVA, A
KEHRL, JH
FASEB JOURNAL, 1994, 8 (05): : A788 - A788

← 1 2 3 4 5 →